Marvel Biosciences (TSXV:MRVL) EV-to-EBIT : -3.30 (As of Sep. 22, 2024)

Marvel Biosciences EV-to-EBIT Chart

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
EV-to-EBIT	Get a 7-Day Free Trial											-1.91	-1.61	-1.41	-2.09	-3.69

Competitive Comparison of Marvel Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Marvel Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's EV-to-EBIT falls into.

Marvel Biosciences EV-to-EBIT Calculation

Marvel Biosciences's EV-to-EBIT for today is calculated as:

Marvel Biosciences's current Enterprise Value is C$6.66 Mil.
Marvel Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences  (TSXV:MRVL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Marvel Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2024 is calculated as:

Marvel Biosciences's Enterprise Value for the quarter that ended in Apr. 2024 was C$7.45 Mil.
Marvel Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description